(Total Views: 368)
Posted On: 04/26/2021 7:20:38 PM
Post# of 69
MindMed 18-MC Trial - Connecting the Dots to J&J - Updated & Revised
MindMed is set to list on the NASDAQ tomorrow as $MNMD - you can see the official release to this here:
https://www.prnewswire.com/news-releases/mind..._cleartime
Plus the Office Letter concerning Form 8-A 12(b) Registration from SEC (NASDAQ)
https://www.sec.gov/Archives/edgar/data/18138...t_MNMD.pdf
---
A Study to Assess 18-Methoxycoronaridine
https://www.clinicaltrials.gov/ct2/show/NCT04...amp;rank=1
The current contact for this trial is listed as:
Rob Barrow... he replaced the contacts below who were originally listed on the Trial Data when this PR dropped on Feb. 2, 2021... which makes sense since he is the Business Development Officer:
https://www.prnewswire.com/news-releases/mind...19840.html
---
The ORIGINAL contacts on this trial work for Janssen Pharmaceutical Companies were:
Jason Summa - https://www.linkedin.com/in/jasonsumma/
Jamie Freedman - https://www.linkedin.com/in/jamie-freedman-0543104/
You can proof this by looking at the revision history of the Trial... Look at Version 5 of the document.
https://www.clinicaltrials.gov/ct2/history/NC...udyPageTop
Both of these folks are tied to Johnson & Johnson via Janssen... I don't think that is a coincidence.
They are working with Linear Clinical Research Ltd in Australia / Perth. According to the website:
Australian (TGA) clinical trial start-ups are typically 4-6 months faster than US (FDA) trials. Better still, they’re much cheaper – often a third of the cost and exceptional quality.
No IND required
Fast-tracked approvals
Generous R&D refunds
Excellent health system Access to patient databases
Data accepted by FDA, EMA, CFDA & PDMA
---
Looks like to me they will fast track in Australia - then partner with J&J if successful.
MindMed is set to list on the NASDAQ tomorrow as $MNMD - you can see the official release to this here:
https://www.prnewswire.com/news-releases/mind..._cleartime
Plus the Office Letter concerning Form 8-A 12(b) Registration from SEC (NASDAQ)
https://www.sec.gov/Archives/edgar/data/18138...t_MNMD.pdf
---
A Study to Assess 18-Methoxycoronaridine
https://www.clinicaltrials.gov/ct2/show/NCT04...amp;rank=1
The current contact for this trial is listed as:
Rob Barrow... he replaced the contacts below who were originally listed on the Trial Data when this PR dropped on Feb. 2, 2021... which makes sense since he is the Business Development Officer:
https://www.prnewswire.com/news-releases/mind...19840.html
---
The ORIGINAL contacts on this trial work for Janssen Pharmaceutical Companies were:
Jason Summa - https://www.linkedin.com/in/jasonsumma/
Jamie Freedman - https://www.linkedin.com/in/jamie-freedman-0543104/
You can proof this by looking at the revision history of the Trial... Look at Version 5 of the document.
https://www.clinicaltrials.gov/ct2/history/NC...udyPageTop
Both of these folks are tied to Johnson & Johnson via Janssen... I don't think that is a coincidence.
They are working with Linear Clinical Research Ltd in Australia / Perth. According to the website:
Australian (TGA) clinical trial start-ups are typically 4-6 months faster than US (FDA) trials. Better still, they’re much cheaper – often a third of the cost and exceptional quality.
No IND required
Fast-tracked approvals
Generous R&D refunds
Excellent health system Access to patient databases
Data accepted by FDA, EMA, CFDA & PDMA
---
Looks like to me they will fast track in Australia - then partner with J&J if successful.
(0)
(0)Scroll down for more posts ▼
